Idorsia Highlights Aprocitentan Efficacy in Obesity, Cardiometabolic Patients at AHA Hypertension 2026
Event summary
- Idorsia to present two oral sessions at AHA Hypertension 2026 on October 10, 2026, detailing aprocitentan's efficacy in obesity and cardiometabolic patients.
- PRECISION study analyses show aprocitentan's potential in resistant hypertension across cardiovascular-kidney-metabolic (CKM) continuum.
- 69.2% of PRECISION patients were obese or severely obese, 54.1% had diabetes, and 63% were on ≥4 antihypertensive therapies.
- Aprocitentan approved as TRYVIO® in US (2024) and JERAYGO™ in EU/UK/Canada for resistant hypertension.
The big picture
Idorsia's presentation underscores the growing importance of endothelin pathway blockade in managing difficult-to-control hypertension, particularly in high-risk populations like those with obesity and cardiometabolic comorbidities. The findings come as the prevalence of obesity and associated hypertension continues to rise globally, creating a significant unmet need. Aprocitentan's dual endothelin receptor antagonism represents a differentiated approach in a competitive hypertension market, with potential to capture share in resistant hypertension segments.
What we're watching
- Market Expansion
- Whether Idorsia can leverage these findings to expand aprocitentan's market share in obesity-associated hypertension.
- Regulatory Dynamics
- The pace at which approvals for aprocitentan may expand into additional indications or regions.
- Competitive Positioning
- How these results position aprocitentan against emerging endothelin pathway inhibitors.
Related topics
